The PathoFinder company

The PathoFinder company

PathoFinder is a privately owned molecular diagnostics company founded in 2004. The company focuses on the development and commercialization of a new generation of molecular diagnostics, with special emphasis on infectious diseases. Our proprietary MultiFinder® and SmartFinder® technologies allows for the detection and differentiation of up to 22 viral and bacterial pathogens in a single assay.

PathoFinder is based in Maastricht, The Netherlands. The company’s founder and CEO is Guus Simons, Ph.D.

Before founding PathoFinder, Guus Simons worked for eleven years at Keygene, Wageningen, The Netherlands, where he held positions as project manager and business manager and for nine years as project leader at the Netherlands Institute for Dairy Research. He performed his post-doc period at the University of Ghent, Belgium after he got his Ph.D. in molecular biology at the University of Nijmegen, The Netherlands. Guus Simons has written more than 50 peer reviewed papers and 15 patent applications.

Mission statement

PathoFinder is dedicated to the development, validation and production of high quality, sensitive and robust multiplex assays for the detection of multiple pathogens in a single assay.

Our products are designed to work on many commercially available detection systems to enable a rapid introduction into molecular diagnostics laboratories.

PathoFinder will continue to develop new assays for several panel diseases like Respiratory Tract Infections (RTI's), Gastroenteritis, Human Papilloma Virus, Viral Meningitis and Sexually Transmitted Diseases (STD's).

ISO 13485:2003 and Quality Control

ISO 13485:2003 and Quality Control

PathoFinder has a ISO 13485:2003 certified Quality Management System for the production, marketing, sales and distribution of In-Vitro Diagnostics for infectious diseases.

Quality Control for Molecular Diagnostics (QCMD, is an international Extenal Quality Assessment (EQA) provider for molecular diagnosis of infectious agents. QCMD has an extensive EQA portfolio with a wide range of clinical relevant infectious diseases and includes schemes for the assessment of microbial load, genotyping and drug resistance.

In the past years PathoFinder has successfully participated in many EQA programs for both the MultiFinder®, SmartFinder® as well as the RealAccurate® products. Details of these tests are available on request.


There are currently no vacancies.

We are always interested in hearing from experienced scientists and managers who would like to work with us.

Therefore, please feel free to send us your CV ( should you wish to be considered for other vacancies that may arise in the future.